186 related articles for article (PubMed ID: 15894662)
1. Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer.
Cramer DW; Titus-Ernstoff L; McKolanis JR; Welch WR; Vitonis AF; Berkowitz RS; Finn OJ
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1125-31. PubMed ID: 15894662
[TBL] [Abstract][Full Text] [Related]
2. Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer.
Terry KL; Titus-Ernstoff L; McKolanis JR; Welch WR; Finn OJ; Cramer DW
Cancer Epidemiol Biomarkers Prev; 2007 Jan; 16(1):30-5. PubMed ID: 17220329
[TBL] [Abstract][Full Text] [Related]
3. Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation.
Hermsen BB; Verheijen RH; Menko FH; Gille JJ; van Uffelen K; Blankenstein MA; Meijer S; van Diest PJ; Kenemans P; von Mensdorff-Pouilly S
Eur J Cancer; 2007 Jul; 43(10):1556-63. PubMed ID: 17532207
[TBL] [Abstract][Full Text] [Related]
4. Determination of MUC1 in sera of ovarian cancer patients and in sera of patients with benign changes of the ovaries with CA15-3, CA27.29, and PankoMab.
Jeschke U; Wiest I; Schumacher AL; Kupka M; Rack B; Stahn R; Karsten U; Mayr D; Friese K; Dian D
Anticancer Res; 2012 May; 32(5):2185-9. PubMed ID: 22593508
[TBL] [Abstract][Full Text] [Related]
5. Potential application of alternatively glycosylated serum MUC1 and MUC5AC in gastric cancer diagnosis.
Xu Y; Zhang L; Hu G
Biologicals; 2009 Jan; 37(1):18-25. PubMed ID: 18848467
[TBL] [Abstract][Full Text] [Related]
6. Talc and anti-MUC1 antibodies.
Muscat J; Huncharek M; Cramer DW
Cancer Epidemiol Biomarkers Prev; 2005 Nov; 14(11 Pt 1):2679; author reply 2680. PubMed ID: 16284398
[No Abstract] [Full Text] [Related]
7. Perineal exposure to talc and ovarian cancer risk.
Harlow BL; Cramer DW; Bell DA; Welch WR
Obstet Gynecol; 1992 Jul; 80(1):19-26. PubMed ID: 1603491
[TBL] [Abstract][Full Text] [Related]
8. Tissue and serum MUC1 mucin detection in breast cancer patients.
Croce MV; Isla-Larrain MT; Demichelis SO; Gori JR; Price MR; Segal-Eiras A
Breast Cancer Res Treat; 2003 Oct; 81(3):195-207. PubMed ID: 14620915
[TBL] [Abstract][Full Text] [Related]
9. Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer: antigens for multi-targeted antibody-guided therapy.
Chauhan SC; Vinayek N; Maher DM; Bell MC; Dunham KA; Koch MD; Lio Y; Jaggi M
J Histochem Cytochem; 2007 Aug; 55(8):867-75. PubMed ID: 17478446
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor antibodies in ovarian cancer.
Luborsky JL; Barua A; Shatavi SV; Kebede T; Abramowicz J; Rotmensch J
Am J Reprod Immunol; 2005 Aug; 54(2):55-62. PubMed ID: 16105096
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum?
Jordan SJ; Green AC; Whiteman DC; Webb PM;
Gynecol Oncol; 2007 Nov; 107(2):223-30. PubMed ID: 17662378
[TBL] [Abstract][Full Text] [Related]
12. Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance.
Wang L; Ma J; Liu F; Yu Q; Chu G; Perkins AC; Li Y
Gynecol Oncol; 2007 Jun; 105(3):695-702. PubMed ID: 17368732
[TBL] [Abstract][Full Text] [Related]
13. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.
Dieplinger H; Ankerst DP; Burges A; Lenhard M; Lingenhel A; Fineder L; Buchner H; Stieber P
Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1127-33. PubMed ID: 19336561
[TBL] [Abstract][Full Text] [Related]
14. Combined oral contraceptive use and epithelial ovarian cancer risk: time-related effects.
Lurie G; Wilkens LR; Thompson PJ; McDuffie KE; Carney ME; Terada KY; Goodman MT
Epidemiology; 2008 Mar; 19(2):237-43. PubMed ID: 18223481
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis.
Domschke C; Schuetz F; Ge Y; Seibel T; Falk C; Brors B; Vlodavsky I; Sommerfeldt N; Sinn HP; Kühnle MC; Schneeweiss A; Scharf A; Sohn C; Schirrmacher V; Moldenhauer G; Momburg F; Beckhove P
Cancer Res; 2009 Nov; 69(21):8420-8. PubMed ID: 19843863
[TBL] [Abstract][Full Text] [Related]
16. Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients.
Alix-Panabières C; Brouillet JP; Fabbro M; Yssel H; Rousset T; Maudelonde T; Choquet-Kastylevsky G; Vendrell JP
J Immunol Methods; 2005 Apr; 299(1-2):177-88. PubMed ID: 15914200
[TBL] [Abstract][Full Text] [Related]
17. Anti-MUC1 antibodies and ovarian cancer risk: prospective data from the Nurses' Health Studies.
Pinheiro SP; Hankinson SE; Tworoger SS; Rosner BA; McKolanis JR; Finn OJ; Cramer DW
Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1595-601. PubMed ID: 20501761
[TBL] [Abstract][Full Text] [Related]
18. MUC1/X protein immunization enhances cDNA immunization in generating anti-MUC1 alpha/beta junction antibodies that target malignant cells.
Rubinstein DB; Karmely M; Ziv R; Benhar I; Leitner O; Baron S; Katz BZ; Wreschner DH
Cancer Res; 2006 Dec; 66(23):11247-53. PubMed ID: 17145869
[TBL] [Abstract][Full Text] [Related]
19. T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer.
Knutson KL; Krco CJ; Erskine CL; Goodman K; Kelemen LE; Wettstein PJ; Low PS; Hartmann LC; Kalli KR
J Clin Oncol; 2006 Sep; 24(26):4254-61. PubMed ID: 16908932
[TBL] [Abstract][Full Text] [Related]
20. Gender of offspring and maternal risk of invasive epithelial ovarian cancer.
Baik I; Lambe M; Liu Q; Cnattingius S; Mucci LA; Riman T; Ekbom A; Adami HO; Hsieh CC
Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2314-20. PubMed ID: 18006920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
